At BIO 2019 Contract Pharma had a chance to talk with WuXi AppTec’s Felix Hsu, SVP and global head of advanced therapies, about “Make vs Buy” decisions as well as cell and gene therapy market trends.
Additional topics covered were:
- What key factors are influencing “make vs. buy” decisions in the call and gene therapy space?
- How might this paradigm differ from “traditional” pharma development and manufacturing models?
- What are the critical criteria sponsors are looking for from cell and gene therapy service providers?
- How do you see the cell and gene therapy marketing evolving over the next 5 years?
- What is next for WuXi Advanced Therapies on the cell and gene therapy front?